Stemmatters is a biotechnology company operating as a Contract Development and Manufacturing Organisation (CDMO) specialising in regenerative medicine products. Over the years, Stemmatters has built extensive expertise in various products and processes, including cell-based advanced therapy medicinal products (ATMPs) and complex blood-derived biologicals. The company offers a broad spectrum of services, ranging from product/process development and analytical services to GMP-compliant manufacturing and commercialisation.

Headquartered in Portugal, Stemmatters is focused on strengthening its production facility and expanding its service capabilities, combining resources and expertise to accelerate the clinical translation of high-impact medicines. Stemmatters supports the production of: i) novel investigational ATMPs, following high-quality standards and in compliance with regulatory requirements, and ii) non-pharmaceutical products, such as raw materials and intermediate products supporting the manufacturing of cell-based therapies, including culture media supplements and biomaterials. Its biomaterials platform, mimsys®, enhances Stemmatters integrated offering by enabling the development of combination product formulations targeting multiple therapeutic indications.